Navigation Links
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Date:1/28/2008

is similar to that seen in adults.

For more information about Kaletra, please consult your local prescribing information.

Storage Conditions

Kaletra tablets do not require any special storage conditions.

Kaletra oral solution: Store in a refrigerator (2 degrees - 8 degrees C). If kept outside of the refrigerator, do not store above 25 degrees C and discard any unused contents after 42 days (6 weeks). Avoid exposure to excessive heat.

Abbott and HIV/AIDS

Abbott has been a leader in HIV/AIDS research since the early years of the epidemic. In 1985, the company developed the first licensed test to detect HIV antibodies in the blood and remains a leader in HIV diagnostics. Abbott retroviral and hepatitis tests are used to screen more than half of the world's donated blood supply. Abbott has developed two protease inhibitors for the treatment of HIV.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com. For more information on Abbott's HIV/AIDS programs, please visit http://www.abbott.com/HIVAIDS and http://www.abbottglobalcare.org.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
2. Ugandan Children Are Among the First to Receive Abbotts Lower-Strength Aluvia (lopinavir/ritonavir) Tablet
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Actavis Launches Carvedilol Tablets in the U.S.
6. Mylan Announces Final FDA Approval for Carvedilol Tablets
7. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
8. Actavis Launches Amlodipine Tablets in the U.S.
9. Tablet is better all round for cancer patients
10. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
11. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... -- Vasectomy was associated with a small increased risk ... or lethal prostate cancer according to a new study ... found that the association remained even among men who ... lethal cancer cannot be explained by diagnostic bias. It ... to look at the link between vasectomy and prostate ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
(Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... during their younger years, especially women, are less likely ... types struggle with, researchers say. But regular exercise ... if it reached about 150 minutes of moderate to ...
... vaccines targeted against various types of cancer has raised ... however, is that these promising treatments are difficult to ... cellular target to stop cancer growth without inactivating the ... report a laboratory finding that has the potential to ...
... UT Southwestern Medical Center have discovered sets of genes ... survival time and potential new treatments for patients with ... treatment vary widely and often depend on subtle biological ... pharmacology at UT Southwestern and co-lead author of the ...
... The latest weapon against inoperable liver cancer is so ... but according to interventional radiologists at the Indiana University ... therapeutic punch. The glass spheres contain a radioactive ... radiation for a very limited distance so that healthy ...
... HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay News) ... key component of the new U.S. health-care reform law -- ... first successful challenge to the controversial legislation. ... Barack Obama and fellow Democrats against Republicans, will continue to ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Scientists report ... associated with adrenal gland tumors by identifying 13 new ... adrenal gland, which is located above the kidney. These ... be cancerous -- cause the adrenal gland to produce ...
Cached Medicine News:Health News:Regular Exercise While Young May Slow Middle-Age Spread 2Health News:Regular Exercise While Young May Slow Middle-Age Spread 3Health News:UNC scientists discover potential strategy to improve cancer vaccines 2Health News:Gene information predicts survival time, possible new treatment options for lung-cancer patients 2Health News:Y-90 radioembolization offers promise for late-stage liver cancer 2Health News:Health-Care Reform Faces Long Legal Fight 2Health News:Health-Care Reform Faces Long Legal Fight 3Health News:Health-Care Reform Faces Long Legal Fight 4
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... BERNARDINO, Calif., Jan. 25, 2011 Most people know ... know why they should take them or which vitamins ... are getting the vitamins they need, the Stater Bros. ... free 5-minute personal health survey.  The recommendations from this ...
... Jan. 25, 2011 Reportlinker.com announces that a ... catalogue: Emerging Regional Markets for ... The overall emerging markets for ... regions include Latin America, China, Eastern Europe, the ...
Cached Medicine Technology:Stater Bros. Introduces Free Personal Vitamin Recommendation Program 2Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 2Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 3Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 4Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 5
Suture Cutter, 15 Up Curve...
Portal accessory instrument set. Set also includes a package of 8 mm Guide Wires (.15 cm x 38 cm), and Sterilization Tray....
...
Knot tier...
Medicine Products: